WO2009104152A1 - Combination treatment for ovarian cancer - Google Patents

Combination treatment for ovarian cancer Download PDF

Info

Publication number
WO2009104152A1
WO2009104152A1 PCT/IB2009/050682 IB2009050682W WO2009104152A1 WO 2009104152 A1 WO2009104152 A1 WO 2009104152A1 IB 2009050682 W IB2009050682 W IB 2009050682W WO 2009104152 A1 WO2009104152 A1 WO 2009104152A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
paclitaxel
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/050682
Other languages
French (fr)
Inventor
Martine Clozel
Urs Regenass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of WO2009104152A1 publication Critical patent/WO2009104152A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention concerns the combination of an endothelin receptor antagonist of formula (I)
  • paclitaxel for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.
  • Ovarian cancer is one of the most common cancers in women. A common complication of ovarian cancer is ascite formation. Today, there is no satisfactory treatment for ovarian cancer or for its complications such as ascite formation.
  • endothelin receptor antagonists including the compound of formula (I) and the use of said endothelin receptor antagonists in the treatment of various diseases, including cancer in general.
  • Paclitaxel (the active principle of a medicament sold under the trademark Taxol ® in the United States) is an anti-microtubule agent extracted from the needles and bark of the Pacific yew tree, Taxus brevifolia. This compound is currently approved in the European Union and the United States for, among others, the treatment of advanced cancer of the ovary.
  • ET A R endothelin receptor A
  • L. Rosano et al (MoI. Cancer Ther. (2007), 6(7), 2003-2011) disclosed that ZD4054, a specific ET A R antagonist, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
  • the compound of formula (I) which is both an ET A R and an ET B R antagonist, produces surprisingly high effects in an in vivo model of ovarian cancer when combined with paclitaxel.
  • the applicant found that the use of the combination of the compound of formula (I) with paclitaxel prevents the formation of ascites.
  • the compound of formula (I) in combination with paclitaxel may be used for the preparation of a medicament, and is suitable, for the treatment of ovarian cancer and/or the prevention or treatment of ascite formation associated with ovarian cancer.
  • the invention thus firstly relates to a product containing the compound of formula (I) below
  • pharmaceutically acceptable salt refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
  • “Simultaneously” or “simultaneous”, when referring to a therapeutic use, means in the present application that the therapeutic use concerned consists in the administration of two or more active ingredients by the same route and at the same time.
  • “Separately” or “separate”, when referring to a therapeutic use, means in the present application that the therapeutic use concerned consists in the administration of two or more active ingredients at approximately the same time by at least two different routes.
  • Therapeutic administration over a period of time” also encompasses situations wherein the ingredients are not given with the same periodicity
  • prevention of ascite formation or "preventing ascite formation” is meant in the present application that, following the administration of the appropriate preventive treatment according to this invention, the formation of ascites is either avoided or that this formation is reduced, or, alternatively, that the ascites nevertheless formed are eliminated or reduced.
  • treatment of ascite formation or “treating ascite formation” is meant in the present application that, following the administration of the appropriate treatment according to this invention, the ascites present in the patient are eliminated or reduced.
  • the product containing the abovementioned compound of formula (I) or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof will be for therapeutic use, simultaneously, separately or over a period of time, in the prevention or treatment of ascite formation in patients having ovarian cancer.
  • the compound of formula (I) or its pharmaceutically acceptable salt will be intended to be administered by intravenous or intraperitoneal route.
  • the compound of formula (I) or its pharmaceutically acceptable salt will be intended to be administered by oral route.
  • Paclitaxel or its pharmaceutically acceptable salt will preferably be administered by intravenous or intraperitoneal route.
  • a dose of 0.01 to 10 mg (and preferably 0.1 to 5 mg and more preferably 0.1 to 1 mg) of compound of formula (I) per kg of patient body weight per day combined with a dose of 0.1 to 10 mg (and preferably 1 to 3 mg) of paclitaxel per kg of patient body weight per day, will be appropriate.
  • the invention also relates to a pharmaceutical composition containing, as active principles, the compound of formula (I) as defined previously, or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, as well as at least one non-toxic excipient.
  • such a pharmaceutical composition will be in a liquid form suitable for intravenous or intraperitoneal administration.
  • said pharmaceutical composition may contain the compound of formula (I) or a pharmaceutically acceptable salt of this compound and paclitaxel or a pharmaceutically acceptable salt thereof, in solution in a mixture of polyoxyethylated castor oil (e.g. Cremophor ® EL) and ethanol (said mixture containing for example from 40 to 60% in volume of polyoxyethylated castor oil in ethanol).
  • polyoxyethylated castor oil e.g. Cremophor ® EL
  • ethanol e.g. Cremophor ® EL
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing"
  • the invention further relates to the use of the compound of formula (I) as defined previously, or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament intended to treat ovarian cancer. It also relates to the use of the compound of formula (I) as defined previously, or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament intended to prevent or treat ascite formation in patients having ovarian cancer.
  • the invention further relates to a method of treating a patient having an ovarian cancer by administering to said patient a combination of the compound of formula (I) as defined previously or a pharmaceutically acceptable salt of this compound, with paclitaxel or a pharmaceutically acceptable salt thereof. It also relates to a method of preventing or treating the formation of ascites in a patient having an ovarian cancer by administering to said patient a combination of the compound of formula (I) as defined previously or a pharmaceutically acceptable salt of this compound, with paclitaxel or a pharmaceutically acceptable salt thereof.
  • Vehicle solution An aqueous 0.5% (by weight) solution of methylcellulose is prepared by stirring the appropriate quantity of methylcellulose in the appropriate quantity of water for 4 hours. This solution can be prepared up to 3 days in advance. On the day of the experiment, 0.05% (by volume) of Tween 80 is dissolved in the methylcellulose solution previously obtained to yield the vehicle solution.
  • mice 43 mice are injected i.p. with 10 6 SKOV3ipl cells. Ten days later, the tumor weight is evaluated in three of the mice.
  • ⁇ paclitaxel 5 mg/kg (125 ⁇ g paclitaxel in 200 ⁇ L PBS per mouse), once a week, i.p. route; ⁇ ⁇ compound of formula (I): 100 mg/kg (as suspension in the vehicle solution at a concentration of up to 25 mg/mL), once a day, oral route.
  • the combination of the compound of formula (I) with paclitaxel markedly increased the response to the paclitaxel treatment alone: two out often mice were tumor-free after the combination treatment while all mice still had tumors in the paclitaxel-treated group; the average tumor weight in the combination treatment group was reduced compared to the mice treated with the compound of formula (I) alone or with paclitaxel alone; and no mouse treated with the combination developed ascites even though 8 out of 10 still had tumors, whereas ascites were present in 4 out of 9 mice treated with paclitaxel alone and in 6 out of 9 mice treated with the compound of formula (I) alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.

Description

COMBINATION TREATMENT FOR OVARIAN CANCER
The present invention concerns the combination of an endothelin receptor antagonist of formula (I)
Figure imgf000002_0001
(I)
with paclitaxel for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.
Ovarian cancer is one of the most common cancers in women. A common complication of ovarian cancer is ascite formation. Today, there is no satisfactory treatment for ovarian cancer or for its complications such as ascite formation.
PCT publication WO 02/08200 describes endothelin receptor antagonists including the compound of formula (I) and the use of said endothelin receptor antagonists in the treatment of various diseases, including cancer in general.
Paclitaxel (the active principle of a medicament sold under the trademark Taxol® in the United States) is an anti-microtubule agent extracted from the needles and bark of the Pacific yew tree, Taxus brevifolia. This compound is currently approved in the European Union and the United States for, among others, the treatment of advanced cancer of the ovary.
The combination of endothelin receptor A (ETAR) antagonists with paclitaxel in the treatment of ovarian cancer has already been suggested in literature. For example, L. Rosano et al (Cancer Res. (2003), 63, 2447-2453) teach that the selective ETAR antagonist ABT-627 (atrasentan) combined with paclitaxel produced additive antitumor, apoptotic and antiangiogenic effects.
Besides, L. Rosano et al (MoI. Cancer Ther. (2007), 6(7), 2003-2011) disclosed that ZD4054, a specific ETAR antagonist, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
On the other hand, L. Rosano et al (MoI. Cancer Ther. (2006), 5(4), 833-842) also showed that BQ 788, a selective endothelin receptor B (ETBR) antagonist, contrarily to ETAR antagonists, was ineffective in inhibiting cell adhesiveness of ovarian tumor cells in vitro.
The applicant has now found that the compound of formula (I), which is both an ETAR and an ETBR antagonist, produces surprisingly high effects in an in vivo model of ovarian cancer when combined with paclitaxel. Besides, in the same in vivo model, the applicant found that the use of the combination of the compound of formula (I) with paclitaxel prevents the formation of ascites. As a result, the compound of formula (I) in combination with paclitaxel may be used for the preparation of a medicament, and is suitable, for the treatment of ovarian cancer and/or the prevention or treatment of ascite formation associated with ovarian cancer.
The invention thus firstly relates to a product containing the compound of formula (I) below
Figure imgf000003_0001
(I)
or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, as well as to said product for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer. The following paragraphs provide definitions of the various terms used in the present patent application and are intended to apply uniformly throughout the specification and claims, unless an otherwise expressly set out definition provides a broader or narrower definition.
The term "pharmaceutically acceptable salt" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
"Simultaneously" or "simultaneous", when referring to a therapeutic use, means in the present application that the therapeutic use concerned consists in the administration of two or more active ingredients by the same route and at the same time.
"Separately" or "separate", when referring to a therapeutic use, means in the present application that the therapeutic use concerned consists in the administration of two or more active ingredients at approximately the same time by at least two different routes.
By therapeutic administration "over a period of time" is meant in the present application the administration of two or more ingredients at different times, and in particular an administration method according to which the entire administration of one of the active ingredients is completed before the administration of the other or others begins. In this way it is possible to administer one of the active ingredients for several months before administering the other active ingredient or ingredients. In this case, no simultaneous administration occurs. Therapeutic administration "over a period of time" also encompasses situations wherein the ingredients are not given with the same periodicity
(e.g. wherein one ingredient is given once a day and another is given once a week).
By "prevention of ascite formation" or "preventing ascite formation" is meant in the present application that, following the administration of the appropriate preventive treatment according to this invention, the formation of ascites is either avoided or that this formation is reduced, or, alternatively, that the ascites nevertheless formed are eliminated or reduced. By "treatment of ascite formation" or "treating ascite formation" is meant in the present application that, following the administration of the appropriate treatment according to this invention, the ascites present in the patient are eliminated or reduced.
In a preferred embodiment of this invention, the product containing the abovementioned compound of formula (I) or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, will be for therapeutic use, simultaneously, separately or over a period of time, in the prevention or treatment of ascite formation in patients having ovarian cancer.
According to one variant of this invention, the compound of formula (I) or its pharmaceutically acceptable salt will be intended to be administered by intravenous or intraperitoneal route.
According to another variant of this invention, the compound of formula (I) or its pharmaceutically acceptable salt will be intended to be administered by oral route.
Paclitaxel or its pharmaceutically acceptable salt will preferably be administered by intravenous or intraperitoneal route.
Though the exact administration doses of a product according to this invention will have to be determined by the treating physician, it is expected that a dose of 0.01 to 10 mg (and preferably 0.1 to 5 mg and more preferably 0.1 to 1 mg) of compound of formula (I) per kg of patient body weight per day combined with a dose of 0.1 to 10 mg (and preferably 1 to 3 mg) of paclitaxel per kg of patient body weight per day, will be appropriate.
The invention also relates to a pharmaceutical composition containing, as active principles, the compound of formula (I) as defined previously, or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, as well as at least one non-toxic excipient.
Preferably, such a pharmaceutical composition will be in a liquid form suitable for intravenous or intraperitoneal administration. In particular, said pharmaceutical composition may contain the compound of formula (I) or a pharmaceutically acceptable salt of this compound and paclitaxel or a pharmaceutically acceptable salt thereof, in solution in a mixture of polyoxyethylated castor oil (e.g. Cremophor® EL) and ethanol (said mixture containing for example from 40 to 60% in volume of polyoxyethylated castor oil in ethanol).
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing"
[published by Lippincott Williams & Wilkins]) by bringing the described compounds or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The invention further relates to the use of the compound of formula (I) as defined previously, or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament intended to treat ovarian cancer. It also relates to the use of the compound of formula (I) as defined previously, or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament intended to prevent or treat ascite formation in patients having ovarian cancer.
The invention further relates to a method of treating a patient having an ovarian cancer by administering to said patient a combination of the compound of formula (I) as defined previously or a pharmaceutically acceptable salt of this compound, with paclitaxel or a pharmaceutically acceptable salt thereof. It also relates to a method of preventing or treating the formation of ascites in a patient having an ovarian cancer by administering to said patient a combination of the compound of formula (I) as defined previously or a pharmaceutically acceptable salt of this compound, with paclitaxel or a pharmaceutically acceptable salt thereof.
Besides, preferences indicated for the product according to this invention of course apply mutatis mutandis to the pharmaceutical compositions and uses of this invention.
Particular embodiments of the invention are described in the following section, which serves to illustrate the invention in more detail without limiting its scope in any way. Pharmacological properties of the invention product
Human SKOV3ipl tumor growth inhibition assay in mice
Experimental methods:.
Vehicle solution An aqueous 0.5% (by weight) solution of methylcellulose is prepared by stirring the appropriate quantity of methylcellulose in the appropriate quantity of water for 4 hours. This solution can be prepared up to 3 days in advance. On the day of the experiment, 0.05% (by volume) of Tween 80 is dissolved in the methylcellulose solution previously obtained to yield the vehicle solution.
Experimental procedure
43 mice are injected i.p. with 106 SKOV3ipl cells. Ten days later, the tumor weight is evaluated in three of the mice. Treatment with a suspension of the compound of formula (I) in the vehicle solution (10 mice), paclitaxel diluted 1 :6 in phosphate buffered saline (PBS) for i.p. injections (10 mice), a suspension of the compound of formula (I) in the vehicle solution as well as paclitaxel diluted 1 :6 in PBS for i.p. injections (10 mice), or the vehicle solution only (10 mice), the vehicle solution being as described above, is administered to the mice using the following doses, frequencies and routes:
❖ paclitaxel: 5 mg/kg (125 μg paclitaxel in 200 μL PBS per mouse), once a week, i.p. route; ♦♦♦ compound of formula (I): 100 mg/kg (as suspension in the vehicle solution at a concentration of up to 25 mg/mL), once a day, oral route.
After one month of treatment, the tumor incidence and weight are determined in each of the mice. At the same time, the ascite incidence and volume are also determined. Results:
The following results were obtained with respect to tumor incidence and weight:
Figure imgf000008_0001
S.D. = standard deviation CF(I) = compound of formula (I)
The following results were obtained with respect to ascite incidence and volume:
Figure imgf000008_0002
S.D. = standard deviation CF(I) = compound of formula (I)
As can be seen, the combination of the compound of formula (I) with paclitaxel markedly increased the response to the paclitaxel treatment alone: two out often mice were tumor-free after the combination treatment while all mice still had tumors in the paclitaxel-treated group; the average tumor weight in the combination treatment group was reduced compared to the mice treated with the compound of formula (I) alone or with paclitaxel alone; and no mouse treated with the combination developed ascites even though 8 out of 10 still had tumors, whereas ascites were present in 4 out of 9 mice treated with paclitaxel alone and in 6 out of 9 mice treated with the compound of formula (I) alone.

Claims

Claims
1. A product containing the compound of formula (I) below
Figure imgf000010_0001
(I)
or a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof.
2. The product of claim 1 , for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer.
3. The product of claim 1 for therapeutic use, simultaneously, separately or over a period of time, in the prevention or treatment of ascite formation in patients having ovarian cancer.
4. The product of claim 2 or 3, wherein the compound of formula (I) or its pharmaceutically acceptable salt is intended to be administered by intravenous or intraperitoneal route.
5. The product of claim 2 or 3, wherein the compound of formula (I) or its pharmaceutically acceptable salt is intended to be administered by oral route.
6. The product of one of claims 2 to 5, wherein paclitaxel or its pharmaceutically acceptable salt is intended to be administered by intravenous or intraperitoneal route.
7. A pharmaceutical composition containing, as active principle, the product of claim 1 , as well as at least one non-toxic excipient.
8. A pharmaceutical composition according to claim 7, which is in a liquid form suitable for intravenous or intraperitoneal administration.
9. A pharmaceutical composition according to claim 8, which contains the compound of formula (I), or a pharmaceutically acceptable salt of this compound, and paclitaxel, or a pharmaceutically acceptable salt thereof, in solution in a mixture of polyoxyethylated castor oil and ethanol.
10. A pharmaceutical composition according to claim 9, wherein the mixture of polyoxyethylated castor oil and ethanol is such that it contains from 40 to 60% in volume of polyoxyethylated castor oil in ethanol.
11. Use of the product of claim 1 for the manufacture of a medicament intended to treat ovarian cancer.
Figure imgf000011_0001
(I)
or of a pharmaceutically acceptable salt of this compound, in combination with paclitaxel, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament intended to treat ovarian cancer.
12. Use of the product of claim 1 for the manufacture of a medicament intended to prevent or treat ascite formation in patients having ovarian cancer.
PCT/IB2009/050682 2008-02-20 2009-02-19 Combination treatment for ovarian cancer Ceased WO2009104152A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008050609 2008-02-20
IBPCT/IB2008/050609 2008-02-20

Publications (1)

Publication Number Publication Date
WO2009104152A1 true WO2009104152A1 (en) 2009-08-27

Family

ID=40600259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/050682 Ceased WO2009104152A1 (en) 2008-02-20 2009-02-19 Combination treatment for ovarian cancer

Country Status (1)

Country Link
WO (1) WO2009104152A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702057A4 (en) * 2011-04-25 2015-03-04 Savvipharm Inc PHARMACEUTICAL COMPOSITIONS WITH PACLITAXEL OROTATE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008200A2 (en) * 2000-07-21 2002-01-31 Actelion Pharmaceuticals Ltd Arylethene-sulfonamides, their preparation and their use as endothelin antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008200A2 (en) * 2000-07-21 2002-01-31 Actelion Pharmaceuticals Ltd Arylethene-sulfonamides, their preparation and their use as endothelin antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GODARA GEETA ET AL: "Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma", PROSTATE, vol. 65, no. 1, September 2005 (2005-09-01), pages 27 - 34, XP002527398, ISSN: 0270-4137 *
ROSANO LAURA ET AL: "ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation", EXPERIMENTAL BIOLOGY AND MEDICINE (MAYWOOD), vol. 231, no. 6, June 2006 (2006-06-01), pages 1132 - 1135, XP002527397, ISSN: 1535-3702 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702057A4 (en) * 2011-04-25 2015-03-04 Savvipharm Inc PHARMACEUTICAL COMPOSITIONS WITH PACLITAXEL OROTATE
KR101819596B1 (en) 2011-04-25 2018-02-22 사비팜 인크. Pharmaceutical compositions containing paclitaxel orotate

Similar Documents

Publication Publication Date Title
US8541433B2 (en) Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
PL192544B1 (en) Method of and compositions and sets of agents for enhancing oral biological availability of pharmaceutic agents
KR20160023816A (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
JP2010059185A (en) Method, composition and kit for increasing oral bioavailability of pharmaceutical agent
EP2144504A1 (en) Method of treating brain cancer
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
EP2670405B1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
JP2009536956A (en) Anticancer therapy
WO2008033041A1 (en) Cancer treatment
JP2010106019A (en) Agent of prophylaxis, therapy, and or symptom alleviation for peripheral neuropathy resulting from cancer chemotherapy comprising limaprost
WO2009104152A1 (en) Combination treatment for ovarian cancer
WO2024007801A1 (en) Combination therapy of receptor tyrosine kinase inhibitor and biphenyl cyclooctadiene lignan and use thereof
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
HK40116611A (en) Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
CN117243947A (en) Application of daphnetin and combinations containing the same in the preparation of drugs for diabetic complications
JPH11217338A (en) Agent for improving and enhancing effect of medicine using quinoline derivative
CN113271935A (en) Method of treating CNS tumors with tesetaxel
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
HK1072723B (en) Combinations comprising an epothilone derivatives and an imidazotetrazinone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09712367

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09712367

Country of ref document: EP

Kind code of ref document: A1